<?xml version="1.0" encoding="UTF-8"?>
<p>A dose‐effect trend in the mean DSN in Cycle 1 was observed across the three doses of Rolontis with the DSN decreasing with increasing dose: 1.03 days at 45 
 <italic>μ</italic>g/kg, 0.44 days at 135 
 <italic>μ</italic>g/kg, and 0.03 days at 270 
 <italic>μ</italic>g/kg. The difference in Cycle 1 DSN between the Rolontis groups and the pegfilgrastim group was −0.28 days (CI: −0.56, −0.06) at 270 
 <italic>μ</italic>g/kg of Rolontis, 0.14 days (CI: −0.28, 0.64) at 135 
 <italic>μ</italic>g/kg of Rolontis, and 0.72 days (CI: 0.19, 1.27) at 45 
 <italic>μ</italic>g/kg of Rolontis (Table 
 <xref rid="cam41388-tbl-0002" ref-type="table-wrap">2</xref>). The upper limit of the two‐sided 95% CI for the difference was &gt;1 day for the 45 
 <italic>μ</italic>g/kg group, but &lt;1 day for the 135 
 <italic>μ</italic>g/kg and 270 
 <italic>μ</italic>g/kg groups. Therefore, in Cycle 1, noninferiority to pegfilgrastim was demonstrated for the 135 
 <italic>μ</italic>g/kg (
 <italic>P = </italic>0.002) and 270 
 <italic>μ</italic>g/kg (
 <italic>P </italic>&lt;
 <italic> </italic>0.001) Rolontis groups, but not for the 45 
 <italic>μ</italic>g/kg Rolontis group (
 <italic>P </italic>= 0.296). Superiority was demonstrated in the 270 
 <italic>μ</italic>g/kg Rolontis group (0.03 days) compared to the pegfilgrastim group (0.31 days; 
 <italic>P </italic>=
 <italic> </italic>0.023).
</p>
